Drugs / Simvastatin
Simvastatin
also known as
Zocor · MK0733 · SIM · SMV · Simvastatin (Zocor) · Simvastatine · Brand name: Simvastatin Normon, 40 mg · C10AA01 · +15 more
Small molecule targets ABCB1, HMGCR, PTEN via inhibition / activation
Regulatory milestones approvals, filings & regulatory actions · 14 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed chronic kidney disease 1 milestone | |||||
| Filed | US (FDA) | VYTORIN | chronic kidney disease | 2011-07-29 | “Supplemental New Drug Applications (sNDAs) for the cholesterol-lowering medicines VYTORIN (ezetimibe/simvastatin) and ZETIA (ezetimibe) have been accepted for standard review...” merck.com ↗ |
| Approved Indication not stated 3 milestones | |||||
| Approved | EU (EMA) | Cholib | — | 2013-08-26 | europa.eu ↗ |
| Label expansions (11) | US (FDA) | ZOCOR | — | 1995-06-30 – 2003-04-16 | fda.gov ↗ |
| Approved | US (FDA) | ZOCOR | — | 1991-12-23 | fda.gov ↗ |
Trials 385 · started per year
today
US approved 1991
EU approved 2013
1
1
1
1
2
7
3
11
6
15
25
29
28
19
18
29
19
21
12
13
15
9
12
9
11
10
8
10
5
11
10
9
1
199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 014 trials | ||||||
| Phase 0 | NCT06273111 | Nov 2026 → Mar 2028 expected | skin hemangioma | Joyce Teng | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07031778 | Jan 2025 overdue | bone disorder | University of Granada | Recruiting | No outcome recorded |
| Phase 0 | NCT05771675 | Oct 2024 → Dec 2026 expected | chronic pancreatitis, recurrent acute pancreatitis | Cedars-Sinai Medical Center | Recruiting | No outcome recorded |
| Phase 0 | NCT05878158 | Apr 2023 → Jan 2024 | exposure, dental pulp | Ahmad Elheeny | Unknown | No outcome recorded |
| Phase 0 | NCT05464810 | Sep 2022 → Apr 2027 expected | female breast carcinoma, hormone receptor-positive breast cancer, invasive breast carcinoma | Emory University | Recruiting | No outcome recorded |
| Phase 0 | NCT04457089 | Jan 2021 → Nov 2024 | ovarian cancer | Marc Goodman | Completed | No outcome recorded |
| Phase 0 | NCT04514029 | Aug 2020 → Nov 2023 overdue | lymphoma | Masonic Cancer Center, University of Minnesota | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02971410 | Apr 2017 → Nov 2021 | plasma cell myeloma | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 0 | NCT03011931 | Mar 2016 → Jan 2019 | celiac disease | Entero Therapeutics | Completed | No outcome recorded |
| Phase 0 | NCT02534376 | Sep 2015 → Feb 2019 | prostate cancer | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT02548936 | Apr 2015 → Oct 2016 | atherosclerosis | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT02285738 | Dec 2014 → Jul 2017 | cancer | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT01764451 | Mar 2012 → Jan 2016 | famililal cerebral cavernous malformations | University of New Mexico | Terminated | No outcome recorded |
| Phase 0 | NCT00769210 | May 2005 → Jul 2008 | heart failure | University of Utah | Completed | No outcome recorded |
| Phase 175 trials · 1 missed | ||||||
| Phase 1 | NCT07389304 | Mar → Dec 2026 expected | — | Shaheed Benazir Bhutto University Sheringal Dir Upper | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07378293 | Mar → Dec 2026 expected | diabetes mellitus | Shaheed Benazir Bhutto University Sheringal Dir Upper | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06925490 | Jun 2025 → Sep 2026 overdue | pulpitis | Cairo University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06948747 | May → Oct 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06478940 | Aug 2024 → Aug 2025 | dental pulp disorder | Cairo University | Unknown | No outcome recorded |
| Phase 1 | NCT06186622 | Jan → Jul 2024 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05542095 | May 2023 | COVID-19, olfactory nerve disorder | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT05580250 | Nov → Dec 2022 | — | Eli Lilly and Company | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT06207682 | Jun → Aug 2022 | — | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT05306379 | Jan → Apr 2022 | — | Aurinia Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04859452 | May → Jul 2021 | — | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04824898 | Jan 2021 → Sep 2022 | periodontitis, aggressive | Ain Shams University | Unknown | No outcome recorded |
| Phase 1 | NCT05008068 | Aug 2019 → Sep 2020 | — | British University In Egypt | Completed | No outcome recorded |
| Phase 1 | NCT03929744 | Jun 2019 → Nov 2020 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03889795 | Jun 2019 → Dec 2026 expected | malignant pancreatic neoplasm | Danae Hamouda, MD | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03728101 | Nov → Dec 2018 | — | Korea University Guro Hospital | Completed | No outcome recorded |
| Phase 1 | NCT03801733 | Jun → Nov 2018 | — | Akebia Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03086291 | Jan 2018 → Sep 2020 | gastric cancer | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 1 | NCT03329118 | Nov → Dec 2017 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03174041 | Apr → Jun 2017 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02817243 | Mar → Jul 2016 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02675309 | Feb → Mar 2016 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02685462 | Jan → Feb 2016 | — | Tobira Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02547402 | Dec 2015 → Jan 2016 | acute kidney injury | Complexa, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02542969 | Sep → Oct 2015 | — | Madrigal Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02406261 | Apr → Aug 2015 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02431013 | Apr → Aug 2015 | hyperlipidemia, peripheral arterial disease | Ajou University School of Medicine | Unknown | No outcome recorded |
| Phase 1 | NCT02447601 | Mar → May 2015 | type 2 diabetes mellitus | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02390843 | Feb 2015 → Sep 2019 | Ewing sarcoma, Wilms tumor, clear cell sarcoma, germ cell tumor +7 | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT02197234 | Dec 2014 → Apr 2015 | non-small cell lung carcinoma | AstraZeneca | Completed | Mixed |
| Phase 1 | NCT02300259 | Nov 2014 → Apr 2015 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02360826 | Jun 2014 → Jul 2016 | — | Children's Mercy Hospital Kansas City | Completed | No outcome recorded |
| Phase 1 | NCT02156492 | Jun → Dec 2014 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02017639 | Jan 2014 → Mar 2016 | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01978327 | Nov 2013 → Mar 2014 | Alzheimer disease | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT01979185 | Nov → Dec 2013 | — | Shire | Completed | No outcome recorded |
| Phase 1 | NCT01953835 | Oct 2013 → Mar 2014 | systemic lupus erythematosus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01960140 | Oct → Dec 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01725230 | Nov 2012 → Jan 2013 | rheumatoid arthritis | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01642862 | Jul 2012 → Jul 2013 | celiac disease | University of Zurich | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01870466 | Jun 2012 → Sep 2013 | — | Samsung Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01632566 | Jun 2012 → Apr 2013 | — | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1 | NCT01689623 | Jun → Aug 2012 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01469468 | Nov → Dec 2011 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01486433 | Nov 2011 → Mar 2012 | hypertriglyceridemia | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01445860 | Aug → Sep 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01520077 | Jul 2011 → Jan 2015 | alopecia areata | University of Miami | Completed | No outcome recorded |
| Phase 1 | NCT01383395 | Jun → Sep 2011 | — | Samsung Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01304329 | Feb → Apr 2011 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01138072 | Jun → Aug 2010 | HIV infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01147692 | May → Aug 2010 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01101568 | Apr → Jun 2010 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01103739 | Mar → May 2010 | chronic pain syndrome | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01096940 | Mar → Aug 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01299597 | Jan → Feb 2010 | sleep disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00994773 | Dec 2009 → Oct 2011 | hepatitis B virus infection | Bader, Ted, M.D. | Completed | No outcome recorded |
| Phase 1 | NCT00935259 | Jul → Oct 2009 | hyperlipoproteinemia | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 1 | NCT00987558 | Jun → Aug 2009 | epilepsy | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT00924430 | Jun → Jul 2009 | type 2 diabetes mellitus | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00828282 | Mar 2009 → Jan 2011 | chronic lymphocytic leukemia/small lymphocytic lymphoma | John Haslip | Completed | No outcome recorded |
| Phase 1 | NCT00538044 | Jan 2009 → Jan 2012 | pulmonary hypertension | Capital Medical University | Unknown | No outcome recorded |
| Phase 1 | NCT01821027 | Aug → Sep 2008 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 1 | NCT00736606 | Aug → Sep 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00504439 | Jun → Sep 2007 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00652431 | May → Jul 2007 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 1 | NCT00495729 | Apr → Aug 2007 | sleep disorder, initiating and maintaining sleep | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00377442 | Aug 2006 → Apr 2007 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00309374 | Mar → Jul 2006 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 1 | NCT02183623 | Sep → Oct 2005 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00255242 | Jul 2004 → Mar 2008 | cystic fibrosis | Akron Children's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02587390 | May → Jul 2000 | hyperlipidemia | NeuroBo Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02187536 | Apr → May 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00000941 | ? → Mar 2002 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00365001 | ? → Apr 2008 | rheumatoid arthritis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00017758 | — | HIV infectious disease, lipodystrophy | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/214 trials · 2 met primary | ||||||
| Phase 1/2 | NCT07392541 | Jan 2026 → Jan 2028 expected | biliary tract cancer | Tongji Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06553157 | Sep 2024 → Jul 2025 | cancer, platinum-induced ototoxicity | Minia University | Completed | No outcome recorded |
| Phase 1/2 | NCT06030622 | Apr → Dec 2024 | malignant pancreatic neoplasm | State University of New York - Downstate Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT04652089 | Dec 2020 → Sep 2021 | depressive disorder | University of Oxford | Completed | No outcome recorded |
| Phase 1/2 | NCT03599609 | Mar 2018 → Jan 2020 | sickle cell disease, stroke disorder | University of Campinas, Brazil | Unknown | No outcome recorded |
| Phase 1/2 | NCT02061397 | Mar 2014 → Dec 2019 | lymphangioleiomyomatosis, tuberous sclerosis | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1/2 | NCT01654562 | Dec 2012 → Jul 2013 | choroideremia | University of Alberta | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT01702246 | Feb 2012 → May 2015 | sickle cell disease | UCSF Benioff Children's Hospital Oakland | Completed | Met primary |
| Phase 1/2 | NCT01092572 | May 2010 | autoinflammatory syndrome, cystic fibrosis | University of British Columbia | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT00795288 | Aug 2008 → Feb 2013 | subarachnoid hemorrhage | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT00508027 | Jun 2007 → Dec 2011 | sickle cell disease | UCSF Benioff Children's Hospital Oakland | Completed | No outcome recorded |
| Phase 1/2 | NCT00281476 | Feb 2006 → Nov 2007 | plasma cell myeloma | Vejle Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT00180713 | Oct 2005 → Oct 2008 | pulmonary hypertension | Imperial College London | Completed | Met primary |
| Phase 1/2 | NCT00235963 | Dec 2002 → Jan 2006 | intracranial vasospasm, subarachnoid hemorrhage | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 270 trials · 3 met primary · 7 missed | ||||||
| Phase 2 | NCT07625930 | Jan 2027 → Apr 2029 expected | gastroesophageal adenocarcinoma | McGill University Health Centre/Research Institute of the McGill University Health Centre | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07831369 | Sep 2026 → Sep 2027 expected | astrocytoma, IDH-mutant, grade 4, glioblastoma | Inova Health Care Services | Recruiting | No outcome recorded |
| Phase 2 | NCT07662785 | Aug 2026 → Aug 2027 expected | xanthoma | Klira Skin | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07213557 | Mar 2026 → Sep 2027 expected | gastroesophageal cancer | National Cancer Institute, Naples | Recruiting | No outcome recorded |
| Phase 2 | NCT07307989 | Aug 2025 → Jul 2029 expected | hyperlipidemia, ischemic stroke | Chang Gung Memorial Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07003815 | Jun 2025 → Dec 2026 expected | biliary tract cancer | Tongji Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06437574 | Jul 2024 → Feb 2028 expected | prostate cancer | Cedars-Sinai Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07264842 | Jun 2024 → Apr 2026 overdue | dental pulp necrosis | Dow University of Health Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT05586360 | Mar 2024 → Mar 2027 expected | prostate cancer | Medical University of South Carolina | Recruiting | No outcome recorded |
| Phase 2 | NCT05821556 | Jun 2023 → Aug 2026 overdue | pancreatic adenocarcinoma | National Cancer Institute, Naples | Recruiting | No outcome recorded |
| Phase 2 | NCT05550415 | Aug 2022 → Nov 2026 expected | chemotherapy-induced toxicity, statin toxicity, triple-negative breast carcinoma | Universitas Indonesia | Recruiting | No outcome recorded |
| Phase 2 | NCT04985201 | Nov 2021 → Dec 2022 | small cell lung carcinoma | Shanghai Pulmonary Hospital, Shanghai, China | Unknown | No outcome recorded |
| Phase 2 | NCT04698941 | Jul → Dec 2021 | small cell lung carcinoma | Shanghai Pulmonary Hospital, Shanghai, China | Unknown | Met primary |
| Phase 2 | NCT06632834 | Aug 2020 → Jan 2025 overdue | dilated cardiomyopathy | National Taiwan University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04301271 | Aug 2020 → Jun 2024 | major depressive disorder, obesity disorder | Charite University, Berlin, Germany | Completed | Missed primary |
| Phase 2 | NCT04348695 | Apr 2020 → Jan 2021 | COVID-19 | HM Hospitales | Completed | Missed primary |
| Phase 2 | NCT03324425 | Mar 2020 → Dec 2028 expected | breast cancer | Baylor Breast Care Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03329599 | Feb 2019 → Dec 2021 | atherosclerosis | Northern California Institute of Research and Education | Completed | Missed primary |
| Phase 2 | NCT03775070 | Jan 2019 → Jul 2022 | dilated cardiomyopathy | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03400826 | Aug 2018 → Jul 2026 overdue | uterine corpus leiomyoma | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 2 | NCT03454529 | Mar 2018 → Oct 2021 | invasive breast carcinoma | Michael Simon | Completed | No outcome recorded |
| Phase 2 | NCT04418089 | Jan 2018 → May 2019 | breast cancer, chemotherapy-induced toxicity | Indonesia University | Completed | No outcome recorded |
| Phase 2 | NCT03150459 | Jul 2017 → Mar 2018 | cirrhosis of liver | Judit Pich | Completed | No outcome recorded |
| Phase 2 | NCT02946424 | Jul 2017 → Sep 2023 | osteoporosis, spinal cord injury | Craig Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02968810 | Jun 2017 → May 2023 | cirrhosis of liver, hepatocellular carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT03192293 | Jan 2017 → Jan 2019 | breast cancer | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 2 | NCT02743364 | Sep 2016 → Oct 2019 | acute pancreatitis | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT02360618 | Oct 2015 → Jan 2018 | infiltrating bladder urothelial carcinoma | London Health Sciences Centre | Unknown | No outcome recorded |
| Phase 2 | NCT03400475 | Apr 2015 → Oct 2016 | mucositis | Ahmed Mohamed Mahrous | Completed | Missed primary |
| Phase 2 | NCT02399709 | Apr → Oct 2015 | — | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02161822 | Oct 2014 → Dec 2020 | rectum adenocarcinoma | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT04183387 | Sep 2014 → Jan 2016 | uveitis | Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology | Completed | No outcome recorded |
| Phase 2 | NCT02096588 | May 2014 → Apr 2017 | breast cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 2 | NCT02104193 | Apr 2014 → Nov 2015 | metastatic malignant neoplasm in the brain | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT02433535 | Dec 2013 → Aug 2017 | asthma | University of California, Davis | Withdrawn | No outcome recorded |
| Phase 2 | NCT02026583 | Dec 2013 → Apr 2017 | colorectal cancer | Samsung Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01665950 | Aug 2012 → Oct 2014 | bipolar disorder | Massachusetts General Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01771198 | Aug 2012 → Jul 2015 | sinusitis | University of Montreal Hospital Centre (CHUM) | Terminated | No outcome recorded |
| Phase 2 | NCT01517893 | Jan 2012 → Dec 2013 | generalized vitiligo | John Harris | Completed | No outcome recorded |
| Phase 2 | NCT01561482 | Jan 2012 → Jul 2014 | prostate carcinoma | Nicholas Mitsiades | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01439555 | Nov 2011 → Nov 2017 | Alzheimer disease | University of Massachusetts, Worcester | Completed | No outcome recorded |
| Phase 2 | NCT01441349 | Aug 2011 → Oct 2022 | small cell lung carcinoma | National Cancer Center, Korea | Unknown | No outcome recorded |
| Phase 2 | NCT01332617 | Apr 2011 → Feb 2018 | plasma cell myeloma | University of Louisville | Withdrawn | No outcome recorded |
| Phase 2 | NCT01281761 | Nov 2010 → Sep 2012 | colorectal cancer | Samsung Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01156545 | Oct 2010 → Dec 2016 | non-small cell lung carcinoma | National Cancer Center, Korea | Completed | No outcome recorded |
| Phase 2 | NCT01225263 | Sep 2010 → Jan 2015 | migraine disorder | Rami Burstein | Completed | Met primary |
| Phase 2 | NCT01190462 | Aug 2010 → Aug 2012 | colorectal cancer | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT01105975 | Apr 2010 → Jun 2011 | hyperlipidemia | Eli Lilly and Company | Completed | Met primary |
| Phase 2 | NCT01110785 | Apr 2010 → Apr 2012 | colorectal cancer | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT01005290 | Oct 2009 → Oct 2010 | hypertensive disorder | Ferrer Internacional S.A. | Terminated | No outcome recorded |
| Phase 2 | NCT00939822 | Mar 2009 → Sep 2013 | Alzheimer disease | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 2 | NCT00567307 | Jan → Dec 2009 | cardiovascular disorder | Wake Forest University Health Sciences | Completed | Missed primary |
| Phase 2 | NCT00944463 | Oct 2008 → Sep 2013 | malignant pancreatic neoplasm | Samsung Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00718328 | Oct 2008 → Jun 2009 | intracerebral hemorrhage | Johns Hopkins University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00807950 | Mar 2008 → Dec 2014 | breast cancer | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 2 | NCT00528580 | Feb 2008 → Sep 2011 | infectious disease with sepsis | University of Chicago | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00575965 | Nov 2007 → Dec 2011 | Waldenstrom macroglobulinemia | Dana-Farber Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00503763 | Sep 2007 → Mar 2009 | smoldering plasma cell myeloma | Meir Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT00354640 | Jun 2006 → Oct 2008 | breast cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT00452244 | May 2006 → Feb 2011 | lung cancer | National Cancer Center, Korea | Completed | Missed primary |
| Phase 2 | NCT00452634 | Apr 2006 → Nov 2009 | small cell lung carcinoma | National Cancer Center, Korea | Completed | No outcome recorded |
| Phase 2 | NCT00321802 | Apr 2006 → Dec 2012 | paroxysmal atrial fibrillation | University of Calgary | Completed | No outcome recorded |
| Phase 2 | NCT00334542 | Mar 2006 → Jun 2009 | breast cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT00359281 | Mar 2006 → Nov 2007 | — | Aegerion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00313859 | Sep 2005 → Aug 2007 | colorectal cancer, metastatic neoplasm | Samsung Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01500577 | Apr 2005 → Nov 2012 | breast cancer | European Institute of Oncology | Completed | No outcome recorded |
| Phase 2 | NCT00399867 | Apr 2005 → Apr 2007 | plasma cell myeloma | Ludwig-Maximilians - University of Munich | Completed | No outcome recorded |
| Phase 2 | NCT00486044 | Feb 2005 → Jun 2009 | Alzheimer disease | University of Wisconsin, Madison | Completed | Missed primary |
| Phase 2 | NCT00594191 | Mar 2004 → Apr 2007 | cirrhosis of liver, portal hypertension | Hospital Clinic of Barcelona | Completed | No outcome recorded |
| Phase 2 | NCT00441844 | Oct 2002 → Jul 2005 | type 1 diabetes mellitus | University of California, Davis | Completed | No outcome recorded |
| Phase 2/39 trials · 2 missed | ||||||
| Phase 2/3 | NCT04971577 | Feb 2022 → Mar 2027 expected | alcohol abuse, fibrotic liver disease | Anna Cruceta | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04301336 | Nov 2019 → Nov 2020 | sickle cell disease | Beni-Suef University | Completed | No outcome recorded |
| Phase 2/3 | NCT03780673 | Jan 2019 → Dec 2022 | cirrhosis of liver | Judit Pich | Completed | Missed primary |
| Phase 2/3 | NCT03490097 | Dec 2017 → May 2018 | chronic hepatitis C virus infection, metabolic syndrome X | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT02252328 | Sep 2015 → Aug 2018 | uveitis | University College, London | Unknown | No outcome recorded |
| Phase 2/3 | NCT01338324 | Apr 2010 → Jun 2011 | celiac disease | All India Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT00676897 | Feb 2008 → Dec 2010 | infectious disease with sepsis | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 2/3 | NCT00693576 | Apr 2007 → May 2008 | — | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT00109382 | May 2003 → Feb 2007 | transient ischemic attack | University of Calgary | Completed | Missed primary |
| Phase 386 trials · 14 met primary · 4 missed | ||||||
| Phase 3 | NCT05963568 | Apr 2026 → Jan 2029 expected | stroke disorder | Northern California Institute of Research and Education | Recruiting | No outcome recorded |
| Phase 3 | NCT03654053 | Oct 2020 → Dec 2026 expected | cirrhosis of liver | VA Office of Research and Development | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04133792 | Oct 2020 → Mar 2028 expected | primary sclerosing cholangitis | Annika Bergquist | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04343001 | Oct 2020 → Apr 2021 | COVID-19 | London School of Hygiene and Tropical Medicine | Withdrawn | No outcome recorded |
| Phase 3 | NCT03971019 | Mar 2019 → May 2024 | female breast carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03435744 | Jan 2019 → Jun 2021 | major depressive disorder | Pakistan Institute of Living and Learning | Completed | Missed primary |
| Phase 3 | NCT03131726 | Jan 2018 → Jan 2027 expected | disease of orbital part of eye adnexa | Lund University | Recruiting | No outcome recorded |
| Phase 3 | NCT04021498 | Sep 2017 → Mar 2025 | recurrent acute pancreatitis | Enrique de-Madaria | Terminated | Missed primary Stop: Enrollment |
| Phase 3 | NCT02850081 | Jun 2017 → Mar 2020 | carotid stenosis, stroke disorder | Columbia University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02713945 | Jan 2017 → Mar 2023 | Noonan syndrome | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 3 | NCT03134157 | Aug 2016 → Jun 2021 | female infertility | Royan Institute | Unknown | No outcome recorded |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | Mixed |
| Phase 3 | NCT03402204 | Apr → Oct 2014 | ischemic stroke | Thammasat University | Completed | No outcome recorded |
| Phase 3 | NCT01999309 | Oct 2013 → Dec 2019 | schizoaffective disorder, schizophrenia, schizophreniform disorder | Iris Sommer | Completed | No outcome recorded |
| Phase 3 | NCT01944176 | Sep 2013 → Aug 2014 | chronic obstructive pulmonary disease | Mahidol University | Completed | Met primary |
| Phase 3 | NCT01702298 | Dec 2012 → May 2013 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01313702 | Oct 2012 → Apr 2014 | cardiovascular disorder | Hospital do Coracao | Withdrawn | No outcome recorded |
| Phase 3 | NCT01651728 | Jul 2012 → Aug 2013 | pneumonia | Indonesia University | Unknown | No outcome recorded |
| Phase 3 | NCT01646437 | Jun 2012 → Jun 2020 | cardiovascular disorder | Population Health Research Institute | Completed | Mixed |
| Phase 3 | NCT01321255 | Jan 2012 → May 2014 | myocardial infarction | National Center for Cardiovascular Research Carlos III | Completed | Met primary |
| Phase 3 | NCT00994903 | Oct 2011 → Sep 2013 | intestinal neoplasm | University of Auckland, New Zealand | Completed | Missed primary |
| Phase 3 | NCT01335997 | May 2011 → Jan 2012 | hyperlipidemia, combined, 2, hyperlipoproteinemia | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT01294683 | Feb 2011 → Jan 2012 | hyperlipidemia, hyperlipoproteinemia | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT01326676 | Feb 2011 → Jul 2012 | cardiovascular disorder | Imperial College London | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT01266434 | Jan 2011 → Feb 2016 | asthma | Mahidol University | Completed | No outcome recorded |
| Phase 3 | NCT01095185 | Nov 2010 → Sep 2013 | cirrhosis of liver, esophageal varices with bleeding, portal hypertension, portal vein thrombosis | Juan A. Arnaiz | Completed | No outcome recorded |
| Phase 3 | NCT02134626 | Aug 2010 → Apr 2014 | cirrhosis of liver, esophageal varices, portal hypertension | Federal University of Rio de Janeiro | Completed | No outcome recorded |
| Phase 3 | NCT01057537 | Jun 2010 → Jul 2012 | cardiovascular disorder | Imperial College London | Completed | Met primary |
| Phase 3 | NCT01238094 | Apr 2010 → Nov 2013 | colorectal cancer | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT02070133 | May 2009 → Mar 2013 | chronic obstructive pulmonary disease | Hospital Universitari Son Dureta | Completed | No outcome recorded |
| Phase 3 | NCT00782184 | Nov 2008 → Sep 2010 | hyperlipidemia | Organon and Co | Completed | Met primary |
| Phase 3 | NCT00738972 | Jan 2008 → Aug 2010 | hypertensive disorder | Fundación Lindavista del Corazón AC | Terminated | No outcome recorded |
| Phase 3 | NCT00653523 | Dec 2007 → Jun 2009 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00535405 | Nov 2007 → Mar 2009 | hyperlipidemia | Organon and Co | Completed | Met primary |
| Phase 3 | NCT00973115 | Nov 2007 → Aug 2009 | hyperlipidemia | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT00525824 | Aug 2007 → Sep 2008 | atherosclerosis, coronary artery disorder, hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00496730 | Jul 2007 → Aug 2008 | hyperlipidemia | Organon and Co | Completed | Met primary |
| Phase 3 | NCT00479882 | Jun 2007 → Jun 2008 | hyperlipidemia, combined, 2, hyperlipoproteinemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00491530 | Jun 2007 → Nov 2008 | hyperlipidemia, combined, 2 | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00465088 | Apr 2007 → Feb 2008 | hyperlipidemia, combined, 2 | Abbott | Completed | Met primary |
| Phase 3 | NCT00462748 | Mar 2007 → Jun 2008 | hyperlipidemia | Organon and Co | Completed | Met primary |
| Phase 3 | NCT00479713 | Feb 2007 → Mar 2008 | hyperlipoproteinemia | Organon and Co | Completed | Met primary |
| Phase 3 | NCT00409773 | Jan 2007 → Jul 2008 | hyperlipidemia, metabolic syndrome X | Organon and Co | Completed | Met primary |
| Phase 3 | NCT00362934 | Oct 2006 → Aug 2008 | hyperlipidemia | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00395603 | Sep 2006 → Jun 2007 | cardiovascular disorder, diabetes mellitus | Organon and Co | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00362206 | Sep 2006 → Sep 2008 | hyperlipidemia | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00413972 | Apr → Nov 2006 | hyperlipidemia | Organon and Co | Completed | Met primary |
| Phase 3 | NCT00316095 | Apr 2006 → Aug 2007 | hyperlipidemia, hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00289900 | Jan 2006 → Aug 2010 | hyperlipidemia, combined, 2 | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT00267280 | Jan → Dec 2006 | hyperlipidemia | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00267267 | Jan 2006 → Jan 2007 | hyperlipidemia | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00267254 | Jan → Aug 2006 | hyperlipidemia | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00947323 | Jan 2006 → Jul 2008 | erectile dysfunction, vascular disorder | Santa Casa de Porto Alegre | Completed | No outcome recorded |
| Phase 3 | NCT00269217 | Jan 2006 → Jan 2007 | hyperlipidemia, combined, 2, hyperlipoproteinemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00651560 | Nov → Dec 2005 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00349375 | Nov 2005 → Sep 2008 | hyperlipidemia | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00254475 | Nov 2005 → Sep 2006 | essential hypertension, hyperlipoproteinemia | Novartis | Completed | Met primary |
| Phase 3 | NCT00242268 | Oct 2005 → ? | relapsing-remitting multiple sclerosis | Alabama Neurology Associates, PC | Unknown | No outcome recorded |
| Phase 3 | NCT00256178 | Oct 2005 → Mar 2007 | hyperlipidemia | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00110435 | May → Dec 2005 | familial hypercholesterolemia, type 2 diabetes mellitus | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00541697 | Jan → Sep 2005 | type 2 diabetes mellitus | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00132717 | Jan 2005 → Jun 2007 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00093899 | Nov 2004 → Sep 2005 | hyperlipidemia, hyperlipoproteinemia, hypertriglyceridemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00171093 | Sep 2004 → Jan 2006 | essential hypertension, hyperlipidemia | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00650819 | Jun 2004 → Feb 2005 | hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00090298 | Apr → Dec 2004 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00080275 | Mar 2004 → ? | hyperlipidemia | Kos Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00090168 | Jan → Oct 2004 | atherosclerosis, coronary artery disorder, hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00652301 | Jul 2003 → Apr 2004 | — | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092690 | Jun 2003 → Mar 2004 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092664 | Jan → Sep 2003 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00157911 | Dec 2002 → Oct 2003 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00053599 | Dec 2002 → Oct 2007 | Alzheimer disease | National Institute on Aging (NIA) | Completed | No outcome recorded |
| Phase 3 | NCT00092651 | Sep 2002 → Jun 2003 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092157 | May 2002 → Mar 2003 | hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00385931 | Jan 2002 → Apr 2003 | hyperlipidemia, hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00551447 | Jan 2002 → Mar 2003 | coronary artery disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00551876 | Dec 2001 → Jan 2003 | type 2 diabetes mellitus | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00389896 | Jul 2001 → Oct 2002 | — | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092677 | Jan 2001 → Apr 2008 | aortic valve stenosis | Organon and Co | Completed | Missed primary |
| Phase 3 | NCT03885921 | Oct 2000 → Jul 2003 | homozygous familial hypercholesterolemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT03884452 | May 2000 → May 2001 | familial hypercholesterolemia | Organon and Co | Completed | Met primary |
| Phase 3 | NCT00251576 | Nov 1999 → Mar 2004 | acute coronary syndrome | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00000553 | Sep 1994 → Feb 2001 | coronary artery disorder, myocardial ischemia | University of Washington | Completed | No outcome recorded |
| Phase 3 | NCT00004266 | Aug 1993 → Jul 1999 | diabetic kidney disease | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 3 | NCT00082251 | — | hyperlipidemia | Kos Pharmaceuticals | Completed | No outcome recorded |
| Phase 471 trials · 6 met primary · 8 missed | ||||||
| Phase 4 | NCT06856772 | Feb 2025 → Mar 2028 expected | atherosclerotic cardiovascular disease | Tor Biering-Sørensen | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06785727 | Feb 2025 → Dec 2028 expected | transient ischemic attack | Prof. dr. Nathalie van der Velde | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06399783 | Oct 2024 → Oct 2027 expected | alopecia areata | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06523465 | Sep 2024 → Dec 2025 overdue | hypertensive disorder, primary aldosteronism | Third Military Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT07459972 | Mar 2024 → Mar 2025 | cirrhosis of liver, portal hypertension | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 4 | NCT05059626 | Dec 2023 → Dec 2025 overdue | endometriosis | Penn State University | Recruiting | No outcome recorded |
| Phase 4 | NCT05658692 | Oct 2022 → Oct 2023 | acute respiratory distress syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT05613400 | Apr 2022 → Dec 2024 | type 2 diabetes mellitus | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 4 | NCT05133310 | Nov 2021 → Dec 2022 | acute lymphoblastic leukemia, infectious disease with sepsis | Hospital General de Mexico | Unknown | No outcome recorded |
| Phase 4 | NCT05369091 | Dec 2020 → Oct 2021 | bone disorder | Postgraduate Medical Institute, Lahore | Completed | No outcome recorded |
| Phase 4 | NCT02533141 | Oct 2019 → Sep 2020 | — | Medical University of Vienna | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT03452891 | Mar 2019 → Jul 2020 | periodontal disorder | University of Nebraska | Completed | No outcome recorded |
| Phase 4 | NCT03571802 | Jun 2018 → Jun 2025 | hyperlipidemia, obesity disorder | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 4 | NCT04177173 | Sep 2017 → Dec 2018 | rheumatoid arthritis | King Edward Medical University | Completed | No outcome recorded |
| Phase 4 | NCT03419429 | Jan 2016 → Jun 2017 | chronic periodontitis | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT02378064 | May 2015 → Dec 2017 | atherosclerosis, coronary artery disorder | CHEOL WHAN LEE, M.D., Ph.D | Completed | Missed primary |
| Phase 4 | NCT02188121 | Feb 2015 → Oct 2020 | bipolar disorder, cardiovascular disorder, major depressive disorder, schizoaffective disorder +1 | Mclean Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02015988 | Jan 2014 → Sep 2016 | acute coronary syndrome, hypertriglyceridemia, type 2 diabetes mellitus | Dnipropetrovsk State Medical Academy | Unknown | No outcome recorded |
| Phase 4 | NCT01952288 | Sep 2013 → Jun 2017 | traumatic brain injury | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT01563731 | Apr 2013 → Dec 2020 | hypertensive disorder, transient ischemic attack | Istituto Auxologico Italiano | Completed | No outcome recorded |
| Phase 4 | NCT05072405 | Jan → Dec 2013 | — | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT01282398 | Apr 2011 → Apr 2012 | cirrhosis of liver, portal hypertension | Sant Pau Research Institute | Unknown | No outcome recorded |
| Phase 4 | NCT01282385 | Apr 2011 → Apr 2014 | cirrhosis of liver, portal hypertension | Sant Pau Research Institute | Unknown | No outcome recorded |
| Phase 4 | NCT01564875 | Dec 2010 → May 2012 | chronic kidney disease, hyperlipidemia | Hanmi Pharmaceutical Company Limited | Unknown | No outcome recorded |
| Phase 4 | NCT01205347 | Oct 2010 → Sep 2013 | myocardial infarction | Brasilia Heart Study Group | Completed | No outcome recorded |
| Phase 4 | NCT01185236 | Sep 2010 → Aug 2011 | type 2 diabetes mellitus | Seoul National University Hospital | Unknown | Missed primary |
| Phase 4 | NCT01142336 | Jun 2010 → Oct 2015 | Alzheimer disease | University of Washington | Completed | Missed primary |
| Phase 4 | NCT01857843 | Nov 2009 → Nov 2013 | acute coronary syndrome | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT01047423 | Aug 2009 → Aug 2011 | hypertensive disorder | Queen's University, Belfast | Withdrawn | No outcome recorded |
| Phase 4 | NCT00946166 | Jul 2009 → Aug 2011 | — | The University of Texas Health Science Center at San Antonio | Withdrawn | No outcome recorded |
| Phase 4 | NCT01073007 | Apr 2009 → Jun 2014 | ischemic stroke | Hospital Universitari Vall d'Hebron Research Institute | Completed | Missed primary |
| Phase 4 | NCT00817843 | Apr 2009 → Sep 2010 | metabolic syndrome X | dr.Frank L.J. Visseren | Completed | Missed primary |
| Phase 4 | NCT00842920 | Dec 2008 → Aug 2020 | cognitive impairment with or without cerebellar ataxia | Charite University, Berlin, Germany | Unknown | No outcome recorded |
| Phase 4 | NCT00906451 | Nov 2008 → May 2009 | myocardial infarction | Brasilia Heart Study Group | Completed | No outcome recorded |
| Phase 4 | NCT00734123 | Apr 2008 → Apr 2009 | atherosclerosis | Hospital Arnau de Vilanova | Unknown | No outcome recorded |
| Phase 4 | NCT00866229 | Apr 2008 → Mar 2010 | low density lipoprotein cholesterol, mild elevation of, systemic lupus erythematosus | Ramathibodi Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00672464 | Apr 2008 → Dec 2009 | schizoaffective disorder, schizophrenia | Duke University | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT00739050 | Sep 2007 → Feb 2008 | systemic lupus erythematosus | Organon and Co | Terminated | No outcome recorded |
| Phase 4 | NCT00654628 | Aug 2007 → Jul 2009 | hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00678743 | Aug 2007 → Aug 2009 | hyperlipidemia | Provident Clinical Research | Completed | Met primary |
| Phase 4 | NCT00481351 | Jun 2007 → Jan 2010 | coronary artery disorder | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT00404599 | Feb 2007 → Jul 2009 | hypertensive disorder, type 2 diabetes mellitus | Amsterdam UMC, location VUmc | Unknown | No outcome recorded |
| Phase 4 | NCT01061450 | Nov 2006 → Jul 2009 | diastolic heart failure, hypertensive disorder | Brasilia Heart Study Group | Completed | No outcome recorded |
| Phase 4 | NCT00442897 | Sep 2006 → Oct 2008 | hyperlipidemia | Organon and Co | Completed | Met primary |
| Phase 4 | NCT00385658 | Aug 2006 → Mar 2007 | hyperlipidemia | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00423579 | Jul 2006 → Mar 2008 | coronary artery disorder, hyperlipidemia | Organon and Co | Completed | Met primary |
| Phase 4 | NCT00291863 | Feb 2006 | end stage renal failure | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT00492765 | Feb 2006 → Apr 2010 | multiple sclerosis | Biogen | Completed | Missed primary |
| Phase 4 | NCT01035320 | Jan 2006 → Jun 2012 | diabetes mellitus, impaired renal function disease | Karolinska Institutet | Completed | No outcome recorded |
| Phase 4 | NCT00652327 | Dec 2005 → Jul 2007 | hyperlipidemia | Organon and Co | Completed | Met primary |
| Phase 4 | NCT00157924 | Nov 2005 → Sep 2007 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00166504 | Oct 2005 → Oct 2007 | hyperlipidemia | Organon and Co | Completed | Met primary |
| Phase 4 | NCT00535925 | Oct 2005 → Dec 2011 | diabetic kidney disease | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
| Phase 4 | NCT00398294 | May 2005 → Apr 2006 | hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00259441 | Feb 2005 → Mar 2006 | kidney failure | Seoul National University Hospital | Completed | Missed primary |
| Phase 4 | NCT00397826 | Jan 2005 → Jan 2006 | hyperlipidemia | Cardinal Tien Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00189085 | Dec 2004 → Jul 2005 | metabolic syndrome X | UMC Utrecht | Completed | No outcome recorded |
| Phase 4 | NCT00146068 | Sep 2004 → Dec 2007 | multiple sclerosis | University of North Carolina | Completed | No outcome recorded |
| Phase 4 | NCT00317993 | Apr → Jul 2004 | — | University of Cologne | Completed | No outcome recorded |
| Phase 4 | NCT00079638 | Apr 2004 → May 2005 | atherosclerosis, coronary artery disorder, diabetes mellitus, hyperlipidemia +1 | Kos Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00141141 | Jan 2004 → Apr 2007 | hyperlipoproteinemia | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00650663 | Oct 2003 → Sep 2004 | atherosclerosis, hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00125593 | Jun 2003 → Aug 2010 | chronic kidney disease | University of Oxford | Completed | Met primary |
| Phase 4 | NCT00451828 | Mar 2002 → Oct 2004 | coronary artery disorder, hyperlipidemia, hyperlipoproteinemia | UCSF Benioff Children's Hospital Oakland | Completed | No outcome recorded |
| Phase 4 | NCT00330980 | Apr 2000 → Mar 2004 | hyperlipidemia | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT00307307 | Jan 2000 → Sep 2005 | atherosclerosis | University of Pennsylvania | Completed | No outcome recorded |
| Phase 4 | NCT00159835 | Feb 1999 → Mar 2005 | cardiovascular disorder | Pfizer | Completed | Missed primary |
| Phase 4 | NCT00471549 | Jun 1991 → Dec 1993 | type 2 diabetes mellitus | University of Aarhus | Completed | No outcome recorded |
| Phase 4 | NCT00522158 | — | cardiovascular disorder, low density lipoprotein cholesterol, mild elevation of, type 2 diabetes mellitus | Baskent University | Completed | No outcome recorded |
| Phase 4 | NCT00450840 | — | infectious disease with sepsis | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 4 | NCT00306826 | ? → May 2009 | glucose metabolism disease | University of Leipzig | Withdrawn | No outcome recorded Stop: Business |
| Phase not applicable46 trials · 2 met primary · 4 missed | ||||||
| — | NCT07704918 | Dec 2026 → Dec 2027 expected | melanoma | University of Colorado, Denver | Not yet recruiting | No outcome recorded |
| — | NCT07102979 | Sep → Dec 2025 overdue | cirrhosis of liver | Chang Gung Memorial Hospital | Enrolling by invitation | No outcome recorded |
| — | NCT06431919 | Jun 2025 → Jan 2028 expected | acute kidney injury, cirrhosis of liver, cirrhotic cardiomyopathy, diastolic heart failure | Post Graduate Institute of Medical Education and Research, Chandigarh | Recruiting | No outcome recorded |
| — | NCT07692620 | Jun 2025 → May 2026 | tooth disorder | Maruwan Ali Alteer | Completed | No outcome recorded |
| — | NCT05677945 | Mar 2023 → Mar 2024 | dental pulp necrosis | Cairo University | Unknown | No outcome recorded |
| — | NCT05525013 | Oct 2022 → Jun 2024 | periapical periodontitis | Cairo University | Completed | No outcome recorded |
| — | NCT05187715 | Feb 2022 → Oct 2023 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| — | NCT04973800 | Jul 2021 → Feb 2023 | depressive disorder | University of Oxford | Completed | No outcome recorded |
| — | NCT07823751 | Apr 2021 → Apr 2023 | breast carcinoma | Universitas Indonesia | Completed | No outcome recorded |
| — | NCT04575090 | Mar 2016 → Feb 2017 | statin toxicity | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| — | NCT02465645 | Jun 2015 → Jan 2017 | esophageal varices | Institute of Liver and Biliary Sciences, India | Completed | Missed primary |
| — | NCT01653223 | Jan 2013 → Dec 2024 overdue | congenital heart disease, heart valve disorder | Sun Yat-sen University | Recruiting | No outcome recorded |
| — | NCT01772719 | Aug 2012 → Nov 2016 | plasma cell myeloma | University of Louisville | Terminated | No outcome recorded |
| — | NCT01506505 | Jul 2012 → Jul 2013 | cerebrovascular disorder, peripheral arterial disease | UMC Utrecht | Completed | Mixed |
| — | NCT01634906 | Jul 2012 → Mar 2013 | atherosclerosis, hyperlipidemia | Sint Franciscus Gasthuis | Completed | No outcome recorded |
| — | NCT01364675 | Jan 2012 → Jul 2016 | hypertensive disorder, prediabetes syndrome | Ramathibodi Hospital | Unknown | No outcome recorded |
| — | NCT01434745 | Sep 2011 → Oct 2014 | Smith-Lemli-Opitz syndrome | Oregon Health and Science University | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00926055 | Sep 2011 → Sep 2012 | atherosclerosis | Korea University | Withdrawn | No outcome recorded |
| — | NCT01382511 | Jul 2011 → Dec 2014 | pachyonychia congenita | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| — | NCT01178710 | Sep 2010 → Jun 2011 | congenital heart disease, heart valve disorder, rheumatic heart disease | Sun Yat-sen University | Completed | No outcome recorded |
| — | NCT01259791 | Sep 2010 → Aug 2013 | statin toxicity | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | Missed primary |
| — | NCT01179464 | Aug 2010 → May 2013 | metastatic carcinoma in the bone | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| — | NCT01085149 | May → Oct 2010 | hyperlipidemia | Hadassah Medical Organization | Unknown | No outcome recorded |
| — | NCT01106495 | May 2010 → Oct 2018 | atherosclerosis | Sun Yat-sen University | Completed | No outcome recorded |
| — | NCT01241097 | Mar → Dec 2010 | — | Federal University of Bahia | Unknown | No outcome recorded |
| — | NCT00995670 | Mar 2010 → Sep 2013 | hyperglycemia | US Department of Veterans Affairs | Completed | No outcome recorded |
| — | NCT00990834 | Nov 2009 → Jun 2011 | myopathy | Scripps Health | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT02304926 | Jan 2009 → Dec 2011 | hyperlipidemia | FISABIO Foundation | Completed | No outcome recorded |
| — | NCT00879710 | Aug 2008 → Jul 2013 | hyperlipoproteinemia, type 1 diabetes mellitus, type 2 diabetes mellitus | Medical College of Wisconsin | Completed | No outcome recorded |
| — | NCT00605995 | Feb 2008 → Aug 2011 | schizophrenia | New York State Psychiatric Institute | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00746603 | Jan 2008 → Jul 2009 | carotid artery disorder | Columbia University | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00531882 | Sep 2007 → Feb 2009 | cystic fibrosis | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| — | NCT00487461 | May 2007 → Feb 2009 | acquired aneurysmal subarachnoid hemorrhage, intracranial vasospasm | University of Illinois at Chicago | Terminated | No outcome recorded |
| — | NCT01700530 | May 2007 → May 2011 | metabolic syndrome X, obesity disorder | University of Kansas Medical Center | Completed | Met primary |
| — | NCT00475826 | Apr 2007 → ? | familial hypercholesterolemia | University of Sao Paulo | Unknown | No outcome recorded |
| — | NCT00365742 | Apr → Jun 2006 | hyperlipidemia | Chestnut Hill Health System | Completed | No outcome recorded |
| — | NCT00587678 | Jan 2006 → Oct 2009 | peripheral arterial disease | University of Virginia | Completed | Missed primary |
| — | NCT00285181 | Nov 2005 → Apr 2007 | — | University Hospital, Montpellier | Completed | No outcome recorded |
| — | NCT00396513 | Sep 2005 → ? | polycystic ovary syndrome | Poznan University of Medical Sciences | Unknown | No outcome recorded |
| — | NCT00461968 | Feb 2005 → Apr 2007 | low density lipoprotein cholesterol, mild elevation of | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| — | NCT00114504 | Sep 2004 → Apr 2007 | atherosclerosis | Kurume University | Completed | No outcome recorded |
| — | NCT00365638 | Apr 2004 → Feb 2005 | polycystic ovary syndrome | Poznan University of Medical Sciences | Completed | Met primary |
| — | NCT00309712 | Aug 2002 → Sep 2006 | hyperlipidemia, combined, 2, type 2 diabetes mellitus | Intermountain Health Care, Inc. | Completed | Missed primary |
| — | NCT00125060 | Aug 2000 → Apr 2004 | heart disorder | Johns Hopkins University | Completed | No outcome recorded |
| — | NCT00905541 | Nov 1998 → Mar 1999 | hyperlipidemia | University Hospital, Bonn | Completed | No outcome recorded |
| — | NCT02511418 | ? → Jan 2007 | chronic renal failure syndrome, hyperlipidemia, hypertensive disorder | Mayo Clinic | Completed | No outcome recorded |
| Comparator or background therapy201 trials | ||||||
| Phase 0 | NCT05682911 Comparator | Jan → Jun 2018 | — | Jinnah Sindh Medical University | Completed | No outcome recorded |
| Phase 0 | NCT00720577 Comparator | Dec 2005 → Jul 2007 | peripheral arterial disease | Medtronic Endovascular | Completed | No outcome recorded |
| Phase 1 | NCT06379958 Comparator | Apr → Sep 2024 overdue | — | Modern Biosciences Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT04178980 Comparator | Jan 2020 → Jan 2022 | statin toxicity | Assiut University | Unknown | No outcome recorded |
| Phase 1 | NCT02871687 Comparator | Apr 2016 → Mar 2021 | — | Brigham and Women's Hospital | Completed | No outcome recorded |
| Show all 201 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 13
| Date | Issuer | Release |
|---|---|---|
| 2016-02-15 | Merck Sharp & Dohme LLC | Regulatory Merck Receives Complete Response Letter from the U.S. FDA for ZETIA® (ezetimibe) and VYTORIN® (ezetimibe and simvastatin) merck.com ↗
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding Merck’s Supplemental New Drug Applications for ZETIA® and VYTORIN® for the reduction of the risk of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, or need for revascularization) in patients with coronary heart disease. |
| 2015-09-01 | Merck Sharp & Dohme LLC | Results New Analyses from the IMPROVE-IT Study with VYTORIN® (ezetimibe and simvastatin) merck.com ↗
Merck (NYSE:MRK), known as MSD in the United States and Canada, today announced results from new analyses from the IMPROVE-IT study. |
| 2015-06-03 | Merck Sharp & Dohme LLC | Results Results from Investigational IMPROVE-IT Study of VYTORIN® (ezetimibe and simvastatin) Published in the New England Journal of Medicine merck.com ↗
Merck (NYSE: MRK ), known as MSD outside the United States and Canada, today announced that the New England Journal of Medicine published the results of the IMPROVE-IT trial, an investigational study comparing treatment with VYTORIN ® (ezetimibe and simvastatin) to treatment with simvastatin alone in more than 18,000 patients presenting with acute coronary syndromes. |
| 2015-03-16 | Merck Sharp & Dohme LLC | Results New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN® (ezetimibe/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes merck.com ↗
VYTORIN reduced total events by 9% vs. simvastatin alone (incidence-rate ratio [IRR] 0.91, 95% CI 0.85-0.97, p=0.007). |
| 2014-11-17 | Merck Sharp & Dohme LLC | Results VYTORIN® (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study merck.com ↗
In IMPROVE-IT, at seven years, 32.7 percent of patients taking VYTORIN experienced a primary endpoint event compared to 34.7 percent of patients taking simvastatin alone (hazard ratio of 0.936, p=0.016). |
| 2012-01-25 | Merck Sharp & Dohme LLC | Regulatory New FDA Approved Labeling For VYTORIN® (Ezetimibe/Simvastatin) Includes Results From the Study of Heart and Renal Protection (SHARP) in Patients With Moderate to Severe Chronic Kidney Disease merck.com ↗ |
| 2011-11-02 | Merck Sharp & Dohme LLC | Regulatory FDA Advisory Committee Unanimously Recommends Approval of Merck’s VYTORIN® (ezetimibe/simvastatin) for Use in Patients with Pre-Dialysis Chronic Kidney Disease merck.com ↗
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) unanimously voted to recommend approval of Merck’s VYTORIN® (ezetimibe/simvastatin) for use in patients with pre-dialysis chronic kidney disease. |
| 2011-10-07 | Merck Sharp & Dohme LLC | Regulatory FDA Approves Merck’s JUVISYNC™ (sitagliptin and simvastatin) Tablets, a Once-Daily Therapy for Patients with Type 2 Diabetes Who Need to Lower Blood Sugar and Cholesterol, Known Risk Factors for Cardiovascular Disease merck.com ↗
The FDA approved JUVISYNC based upon clinical bioequivalence studies in healthy subjects that demonstrated administration of JUVISYNC is equivalent to co-administration of corresponding doses of the two individual medications, sitagliptin and simvastatin, as separate tablets. |
| 2006-12-21 | Perrigo Company | Regulatory Perrigo Company Announces FDA Approval For Simvastatin Tablets perrigo.com ↗
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market Simvastatin Tablets, USP, 5 mg, 10 mg, 20 mg, 40 mg and 80 mg. |
| 2006-06-25 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Receives First U.S. Approval of Generic Zocor® Tablets; Product to be Shipped Immediately tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Merck's Zocor® (Simvastatin) Tablets, 5 mg, 10 mg, 20 mg, and 40 mg. |
| 2006-05-25 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Tentative Approval of Simvastatin Tablets; Provides Update on 180-Day Exclusivity tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration ("FDA") has granted tentative approval for the Company's Ivax Abbreviated New Drug Application ("ANDA") for Simvastatin Tablets USP, 5 mg, 10 mg, 20 mg, 40 mg and 80 mg. |
| 2006-01-01 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Tentative Approval of Simvastatin Tablets tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U. S. Food and Drug Administration has granted tentative approval for the Company's ANDA for Simvastatin Tablets USP, 5 mg, 10 mg, 20 mg, 40 mg and 80 mg. |
| 2003-09-15 | Hovione Scientia Limited | Regulatory Hovione generic product portfolio update hovione.com ↗
Validation for this new generic compound as been successfully completed and a DMF has been filed. |
All press releases naming this drug 21 releases
Evidence & citations 28 cited values
Every value below carries the sentence it was read from. 590 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | simvastatin | “The purpose of this study is to determine whether administration of lapaquistat acetate co-administered with atorvastatin, rosuvastatin or simvastatin (stable statin therapy)...” NCT00249899 ↗581“The purpose of this study is to determine the safety, tolerability and efficacy of a combination therapy interferon beta-1a(Avonex) plus simvastatin (Zocor) vs. interferon...” NCT00146068 ↗ “Cardiovascular Fixed Dose Combination Pill: A Pharmacodynamic Interaction Study to Evaluate the Effect of a Fixed Dose Combination of Acetylsalicylic Acid, Simvastatin and...” NCT01005290 ↗ “One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin,...” NCT04061824 ↗ “Usual dosage for atorvastatin 10-80 mg/tab once daily by mouth; simvastatin 20-80 mg/tab once daily by mouth; pravastatin 10-80 mg/tab once daily by mouth; rosuvastatin 5-20...” NCT00850460 ↗ “Patients remained on ongoing statin therapy (not study provided) of either Atorvastatin 10mg or 20mg; Simvastatin 5mg, 10mg or 20mg; Rosuvastatin 5mg or 10mg; or Pravastatin...” NCT02072161 ↗ “Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.” NCT01326676 ↗ “Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.” NCT01057537 ↗ “Vytorin is a drug combination (Ezetimibe and Simvastatin) that targets the two primary sources of cholesterol, absorption in the gut and synthesis in the liver.” NCT06437574 ↗ “Statin (pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin) at stable dose with or without other LMT as clinically indicated.” NCT02107898 ↗ “Additionally, Cohorts 1 and 3 will include an assessment of potential drug-drug interaction with simvastatin to examine CYP3A4 inhibition by GSK2647544.” NCT01978327 ↗ |
| Known as | Brand name: Simvastatin Normon, 40 mg | “Brand name: Simvastatin Normon, 40 mg” NCT04021498 ↗ |
| Known as | C10AA01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | Flolipid | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | Lacersa | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | MK-733 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | MK0733 | “MK0733, simvastatin / Duration of Treatment: 12 Weeks” NCT00398294 ↗ |
| Known as | NSC-758706 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | Ranzolont | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | SIM | “We recently showed capability of VPA/Simvastatin (SIM) combination to potentiate the antitumor activity of gemcitabine/nab-paclitaxel in vitro and in vivo PDAC preclinical models.” PMID 39300376 ↗ Sep 20242“The investigators hypothesize that simvastatin (SIM) may improve the efficacy of first- line Nivolumab and Oxaliplatin-based chemotherapy” NCT07213557 ↗ “Simvastatin (SIM)” NCT01335997 ↗ |
| Known as | SIMVA | “The purpose of this study was to examine the efficacy and safety of ezetimibe (EZE) coadministered with simvastatin (SIMVA) in a large cohort of African Americans with primary...” PMID 16749654 ↗ May 2006 |
| Known as | Simvador | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | simvastatin (Vytorin) | “simvastatin (Vytorin)” NCT00127218 ↗ |
| Known as | Simvastatin (Zocor) | “Simvastatin (Zocor)” NCT00817843 ↗1“Simvastatin (ZOCOR)” NCT01332617 ↗ |
| Known as | Simvastatin component of juvisync | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | Simvastatin component of polycap | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | Simvastatin component of simcor | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | Simvastatin component of vytorin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | Simvastatina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | Simvastatine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00281476 ↗ |
| Known as | SMV | “Simvastatin (SMV) is one of the family members of statins, it has been showed in many previous studies that the simvastatin when dissolved with methylcellulose in situ gel with...” NCT04824898 ↗2“The purpose of the present study was to investigate the efficacy of autologous Platelet rich fibrin (PRF) or PRF and Simvastatin (SMV) with open flap debridement (OFD) in the...” NCT02120872 ↗ “Atorvastatin (ATV) and Simvastatin (SMV) are specific competitive inhibitors of 3-hydroxy-2-methyl-glutaryl coenzyme A reductase.” NCT02060032 ↗ |
| Known as | Synvinolin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | Zocor | “The purpose of this study is to determine the safety, tolerability and efficacy of a combination therapy interferon beta-1a(Avonex) plus simvastatin (Zocor) vs. interferon...” NCT00146068 ↗13“Both Niaspan (KOS Pharmaceuticals) and simvastatin (Zocor; Merck Pharmaceuticals) are commercially available drugs that are FDA approved for management of hyperlipidemia at the...” NCT00307307 ↗ “The purpose of this study is to see if a drug called simvastatin (brand name Zocor) beneficially affects the level of certain molecules (such as proteins) in the spinal fluid of people.” NCT01142336 ↗ “Name of Drugs: Niaspan (niacin extended-release tablets), Lipitor® (atorvastatin), Zocor® (simvastatin), Zetia™ (ezetimibe), and Crestor® (rosuvastatin)” NCT00079638 ↗ “Simvastatin is a cholesterol-lowering drug approved by the FDA in 1991 and is now commercially available as Zocor (Merck) or as a generic agent.” NCT02534376 ↗ “The second group, run at the same time will take Zocor(simvastatin) 40 mg per day with standard counseling” NCT00365742 ↗ “The drug for treatment of elevated cholesterol is simvastatin (Zocor).” NCT00316095 ↗ “The Rho protein can be inhibited with a drug, simvastatin (Zocor®).” NCT00255242 ↗ “standard-care lipid-lowering therapy: Zocor or Lipitor” NCT01567826 ↗ “simvastatin [Zocor] 20, 40, or 80 mg” PMID 20136164 ↗ 2010 “Simvastatin (Zocor)” NCT00208117 ↗ |
| Known as | Zocor heart-pro | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Action | Inhibit | “simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor)” NCT00004266 ↗ |
| Modality | Small molecule | “statin monotherapy (rosuvastatin [Crestor] 10, 20, or 40 mg; simvastatin [Zocor] 20, 40, or 80 mg;” PMID 20136164 ↗ 2010 |
| Route | Oral | “at tolerable oral doses” NCT00146068 ↗ |
| Target | HMGCR | “Statins, like simvastatin, inhibit the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase” NCT00399867 ↗ |